It’s Time: Precision Oncology
It's time to fully unleash the power of biomarker testing to support precision oncology - all GIST patients should have biomarker (mutational) testing for the best possible personalized treatment plan.
It’s Time: The Life Raft Group Biomarker Testing Campaign – It’s Time for Action
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video shows the action steps of our It's Time campaign.
Colectivo GIST España – la importancia de conocer la mutación de tu gist – SDH – Abril 8, 2021
Lea el artículo para Colectivo GIST España sobre la importancia de conocer la mutación de tu gist - succinato deshidrogenasa - Abril 8, 2021
Colectivo GIST España – la importancia de conocer la mutación de tu gist – Abril 6, 2021
Abril 6, 2021 No nos cansamos de decirlo: la importancia de conocer la mutación de tu gist para optimizar y personalizar el tratamiento El análisis de las mutaciones es probablemente un factor [...]
Thank You for our Major Donor Support During the Pandemic
We took some time to reflect on all we have done virtually as an organization throughout the year. In the midst of this reflection, we wanted to take a breath and say a special thank you to our Major Donors.
Thank You to Our Newest GEMs!
Our GEM Donor Program has a group of new donors that will help the LRG continue the work we do with patients and #GISTresearch. Our thanks go out to our newest GEMs!
Patient of the Month for March: Kamel Ahmed
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Kamel Ahmed shares his story.
The Life Raft Group Medical Advisory Board
The Life Raft Group is pleased to present the members of the LRG 2021 Medical Advisory Board. Members will play a crucial role in offering expert opinions on research and medical developments.
It’s Time: The Life Raft Group Biomarker Testing Campaign – Terminology
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video talks about why it's important and about terminology when talking about mutations.
LRG Represented on Panel About Diversity
The National Organization for Rare Disorders (NORD) held a webinar on February 19th, 2021 for NORD member organizations as well as leaders and staff of nonprofits organizations involved in rare diseases including pharma, patients, caregivers, and advocates.